First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients

Дата публикации: 10-07-2026 12:00:07

Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, underscoring the need for innovative research and new treatments that can improve both survival and quality of life for patients and their families.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New experimental approach may help overcome drug resistance in deadly brain cancer	5	8	09-07-2026
2	Cancer evolution study reveals biology of glioma progression	2	7	10-07-2026
3	Researchers uncover 'hidden key' to immunotherapy for intractable brain tumors	2	8	20-07-2026
4	Brain tumor vaccine links mutation targeting to eight-year survival gains	7	8	06-07-2026
5	Glioblastoma Awareness Day shines light on one of the deadliest forms of brain cancer	0	7.34	15-07-2026
6	Preoperative radiation may enhance brain metastases treatment	5	7	07-07-2026
7	Двойная иммунотерапия рака мозга продлила жизнь пациентам более чем на год	0	0	01-06-2025
8	Lung transplant dramatically improves survival for patients with terminal lung cancer, study finds	7	8	08-07-2026
9	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
10	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 7. Информативность: 8. Источник: medicalxpress.com.